BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 19846527)

  • 1. Novel approach to the formulation of an Epstein-Barr virus antigen-based nasopharyngeal carcinoma vaccine.
    Lutzky VP; Corban M; Heslop L; Morrison LE; Crooks P; Hall DF; Coman WB; Thomson SA; Moss DJ
    J Virol; 2010 Jan; 84(1):407-17. PubMed ID: 19846527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma.
    Taylor GS; Haigh TA; Gudgeon NH; Phelps RJ; Lee SP; Steven NM; Rickinson AB
    J Virol; 2004 Jan; 78(2):768-78. PubMed ID: 14694109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD4 and CD8 T cell responses to tumour-associated Epstein-Barr virus antigens in nasopharyngeal carcinoma patients.
    Lin X; Gudgeon NH; Hui EP; Jia H; Qun X; Taylor GS; Barnardo MC; Lin CK; Rickinson AB; Chan AT
    Cancer Immunol Immunother; 2008 Jul; 57(7):963-75. PubMed ID: 18094968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective treatment of metastatic forms of Epstein-Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy.
    Smith C; Tsang J; Beagley L; Chua D; Lee V; Li V; Moss DJ; Coman W; Chan KH; Nicholls J; Kwong D; Khanna R
    Cancer Res; 2012 Mar; 72(5):1116-25. PubMed ID: 22282657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen.
    Mo WN; Tang AZ; Zhou L; Huang GW; Wang Z; Zeng Y
    Chin Med J (Engl); 2009 May; 122(10):1173-8. PubMed ID: 19493466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and prevalence of CD8(+) T-cell responses directed against Epstein-Barr virus-encoded latent membrane protein 1 and latent membrane protein 2.
    Meij P; Leen A; Rickinson AB; Verkoeijen S; Vervoort MB; Bloemena E; Middeldorp JM
    Int J Cancer; 2002 May; 99(1):93-9. PubMed ID: 11948498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy.
    Kalra M; Gerdemann U; Luu JD; Ngo MC; Leen AM; Louis CU; Rooney CM; Gottschalk S
    Cytotherapy; 2019 Feb; 21(2):212-223. PubMed ID: 30396848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma.
    Duraiswamy J; Sherritt M; Thomson S; Tellam J; Cooper L; Connolly G; Bharadwaj M; Khanna R
    Blood; 2003 Apr; 101(8):3150-6. PubMed ID: 12468425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer.
    Taylor GS; Jia H; Harrington K; Lee LW; Turner J; Ladell K; Price DA; Tanday M; Matthews J; Roberts C; Edwards C; McGuigan L; Hartley A; Wilson S; Hui EP; Chan AT; Rickinson AB; Steven NM
    Clin Cancer Res; 2014 Oct; 20(19):5009-22. PubMed ID: 25124688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human Leukocyte Antigen (HLA) A*1101-Restricted Epstein-Barr Virus-Specific T-cell Receptor Gene Transfer to Target Nasopharyngeal Carcinoma.
    Zheng Y; Parsonage G; Zhuang X; Machado LR; James CH; Salman A; Searle PF; Hui EP; Chan AT; Lee SP
    Cancer Immunol Res; 2015 Oct; 3(10):1138-47. PubMed ID: 25711537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased EBNA-1-specific CD8+ T cells in patients with Epstein-Barr virus-associated nasopharyngeal carcinoma.
    Fogg MH; Wirth LJ; Posner M; Wang F
    Proc Natl Acad Sci U S A; 2009 Mar; 106(9):3318-23. PubMed ID: 19211798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimerically fused antigen rich of overlapped epitopes from latent membrane protein 2 (LMP2) of Epstein-Barr virus as a potential vaccine and diagnostic agent.
    Lin X; Chen S; Xue X; Lu L; Zhu S; Li W; Chen X; Zhong X; Jiang P; Sename TS; Zheng Y; Zhang L
    Cell Mol Immunol; 2016 Jul; 13(4):492-501. PubMed ID: 25864917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts.
    Brooks L; Yao QY; Rickinson AB; Young LS
    J Virol; 1992 May; 66(5):2689-97. PubMed ID: 1313894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes.
    Khanna R; Burrows SR; Nicholls J; Poulsen LM
    Eur J Immunol; 1998 Feb; 28(2):451-8. PubMed ID: 9521052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses.
    Leen A; Meij P; Redchenko I; Middeldorp J; Bloemena E; Rickinson A; Blake N
    J Virol; 2001 Sep; 75(18):8649-59. PubMed ID: 11507210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes.
    Comoli P; Pedrazzoli P; Maccario R; Basso S; Carminati O; Labirio M; Schiavo R; Secondino S; Frasson C; Perotti C; Moroni M; Locatelli F; Siena S
    J Clin Oncol; 2005 Dec; 23(35):8942-9. PubMed ID: 16204009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Sequence analysis of the CTL epitopes in transmembrane region of latent membrane protein 2 of Epstein-Barr virus derived from nasopharyngeal carcinoma cells].
    Zhang NH; Zhang XS; Li J; Zhang RH; Gao YF; Zeng MS
    Ai Zheng; 2006 May; 25(5):566-9. PubMed ID: 16687075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of immune-related molecules in primary EBV-positive Chinese nasopharyngeal carcinoma: associated with latent membrane protein 1 (LMP1) expression.
    Li J; Zhang XS; Xie D; Deng HX; Gao YF; Chen QY; Huang WL; Masucci MG; Zeng YX
    Cancer Biol Ther; 2007 Dec; 6(12):1997-2004. PubMed ID: 18087217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimization of LMP-specific CTL expansion for potential adoptive immunotherapy in NPC patients.
    Lutzky VP; Davis JE; Crooks P; Corban M; Smith MC; Elliott M; Morrison L; Cross S; Tscharke D; Panizza B; Coman W; Bharadwaj M; Moss DJ
    Immunol Cell Biol; 2009; 87(6):481-8. PubMed ID: 19468283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency of Epstein-Barr virus-specific cytotoxic T lymphocytes in the blood of Southern Chinese blood donors and nasopharyngeal carcinoma patients.
    Whitney BM; Chan AT; Rickinson AB; Lee SP; Lin CK; Johnson PJ
    J Med Virol; 2002 Jul; 67(3):359-63. PubMed ID: 12116028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.